Global Mometasone Furoate Ointment Market Size By Type (10g/Box, 15g/Box), By Application (Adults, Adolescents), By Region, And Segment Forecasts, 2023 to 2032

The Global Mometasone Furoate Ointment Market was valued at USD 1.3 billion in 2023 and is projected to reach USD 2.1 billion by 2031, growing at a CAGR of 6.0% during the forecast period from 2023 to 2031. Mometasone furoate ointment, a potent corticosteroid used to treat inflammatory skin conditions such as eczema and psoriasis, is witnessing growing demand due to the increasing prevalence of dermatological disorders, rising awareness about skin health, and the expansion of over-the-counter (OTC) dermatology products. The market is also supported by the surge in teledermatology consultations, making prescriptions more accessible globally.

Drivers:

1. Rising Prevalence of Skin Conditions:

Conditions such as eczema, psoriasis, dermatitis, and allergic reactions are on the rise due to pollution, lifestyle changes, and genetic factors. Mometasone furoate ointment provides effective relief, driving consistent demand.

2. Growth of Teledermatology and e-Prescriptions:

Telehealth platforms have enabled dermatologists to reach wider populations, especially in rural and underserved regions. The ability to diagnose and prescribe remotely has significantly boosted the sales of prescription and OTC topical corticosteroids.

3. OTC Availability and Consumer Awareness:

As consumer awareness of skincare and self-medication increases, many formulations of mometasone are being offered as OTC products in several regions, accelerating market penetration.

Restraints:

1. Potential Side Effects and Regulatory Hurdles:

Extended use of corticosteroids like mometasone may cause skin thinning, hormone disruption, and resistance. This limits long-term use and may attract stricter regulations, impacting market growth.

2. Generic Competition:

The presence of numerous generic alternatives at lower prices creates pricing pressure, particularly in developing regions, affecting the revenue potential for branded pharmaceutical companies.

Opportunity:

1. Expansion into Emerging Markets:

In countries across Asia-Pacific, Latin America, and the Middle East, rising incomes and improvements in healthcare infrastructure are expected to create new opportunities for pharmaceutical companies to introduce high-quality topical treatments.

2. Product Line Expansion and Combinations:

Innovations involving combination products (e.g., mometasone with antifungal agents) or new delivery mechanisms like liposomal or nano-formulated ointments provide growth avenues for companies focused on premium and targeted therapies.

Market by System Type Insights:

Based on formulation, the Ointment segment held the largest share in 2023, owing to its superior efficacy in treating chronic skin conditions that require occlusion and hydration. However, cream and lotion formulations are rapidly gaining popularity due to improved user comfort and suitability for application on broader skin surfaces.

Market by End-use Insights:

Pharmacies and Hospitals were the dominant end-use sectors in 2023, accounting for over 60% of market sales. With prescriptions being the primary source of product distribution, retail pharmacies remain pivotal. However, online pharmacies are expected to grow the fastest, driven by the digital shift in healthcare access and prescription fulfillment.

Market by Regional Insights:

North America led the global mometasone furoate ointment market in 2023, backed by high awareness, strong dermatology infrastructure, and regulatory approvals for multiple product formats. The Asia-Pacific region is poised for the fastest growth, spurred by rising healthcare access, growing cosmetic consciousness, and the increasing burden of skin diseases in densely populated countries like India and China.

Competitive Scenario:

Key players operating in the global mometasone furoate ointment market include:

Merck & Co., Inc.

Glenmark Pharmaceuticals

Taro Pharmaceuticals

Perrigo Company plc

Dr. Reddy’s Laboratories

Teva Pharmaceuticals

Sandoz (Novartis AG)

Apotex Inc.

Cipla Ltd.

Sun Pharmaceutical Industries Ltd.

These companies are focusing on expanding their distribution networks, entering emerging markets, and launching combination therapies to strengthen their position in the market.

Scope of Work – Global Mometasone Furoate Ointment Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.1 billion

CAGR (2023–2031) 6.0%

Market Segments By Formulation, End-Use, Region

Growth Drivers Rising prevalence of skin disorders, expanding telehealth, OTC access

Opportunities Emerging markets, product innovation, combination therapies

Key Market Developments:

2023: Glenmark Pharmaceuticals launched a mometasone-based combination ointment targeting fungal infections with anti-inflammatory properties.

2024: Teva Pharmaceuticals expanded its distribution in Latin America, increasing access to generic mometasone ointment through pharmacy chains.

2025: Cipla Ltd. introduced a nano-liposomal mometasone formulation aimed at reducing side effects and improving skin penetration.

FAQs:

1) What is the current market size of the Global Mometasone Furoate Ointment Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Mometasone Furoate Ointment Market?

The primary growth driver is the rising prevalence of dermatological conditions such as eczema and psoriasis.

3) Which is the largest region during the forecast period in the Global Mometasone Furoate Ointment Market?

North America is the largest regional market due to advanced healthcare access and high awareness.

4) Which segment accounted for the largest market share in Global Mometasone Furoate Ointment Market?

The Ointment formulation segment accounted for the largest market share in 2023.

5) Who are the key market players in the Global Mometasone Furoate Ointment Market?

Key players include Merck & Co., Glenmark Pharmaceuticals, Taro Pharmaceuticals, Teva, Dr. Reddy’s Laboratories, and Cipla Ltd.